Combination of IFNα and poly-I:C reprograms bladder cancer microenvironment for enhanced CTL attraction
Open Access
- 24 March 2015
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 3 (1) , 6
Abstract
Background BCG is a prototypal cancer immunotherapeutic factor currently approved of bladder cancer. In attempt to further enhance the effectiveness of immunotherapy of bladder cancer and, potentially, other malignancies, we evaluated the impact of BCG on local production of chemokines attracting the desirable effector CD8+ T cells (CTLs) and undesirable myeloid-derived suppressor cell (MDSCs) and regulatory T(reg) cells, and the ability of bladder cancer tissues to attract CTLs. Methods Freshly resected bladder cancer tissues were either analyzed immediately or cultured ex vivo in the absence or presence of the tested factors. The expression of chemokine genes, secretion of chemokines and their local sources in freshly harvested and ex vivo-treated tumor explants were analyzed by quantitative PCR (Taqman), ELISAs and immunofluorescence/confocal microscopy. Migration of CTLs was evaluated ex vivo, using 24-transwell plates. Spearman correlation was used for correlative analysis, while paired Students T test or Wilcoxon was used for statistical analysis of the data. Results Bladder cancer tissues spontaneously expressed high levels of the granulocyte/MDSC-attractant CXCL8 and Treg-attractant CCL22, but only marginal levels of the CTL-attracting chemokines: CCL5, CXCL9 and CXCL10. Baseline CXCL10 showed strong correlation with local expression of CTL markers. Unexpectedly, BCG selectively induced only the undesirable chemokines, CCL22 and CXCL8, but had only marginal impact on CXCL10 production. In sharp contrast, the combination of IFNα and a TLR3 ligand, poly-I:C (but not the combinations of BCG with IFNα or BCG with poly-I:C), induced high levels of intra-tumoral production of CXCL10 and promoted CTL attraction. The combination of BCG with IFNα + poly-I:C regimen did not show additional advantage. Conclusions The current data indicate that suboptimal ability of BCG to reprogram cancer-associated chemokine environment may be a factor limiting its therapeutic activity. Our observations that the combination of BCG with (or replacement by) IFNα and poly-I:C allows to reprogram bladder cancer tissues for enhanced CTL entry may provide for new methods of improving the effectiveness of immunotherapy of bladder cancer, helping to extend BCG applications to its more advanced forms, and, potentially, other diseases.Keywords
This publication has 45 references indexed in Scilit:
- CD8+tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcomaInternational Journal of Cancer, 2013
- PGE2-Induced CXCL12 Production and CXCR4 Expression Controls the Accumulation of Human MDSCs in Ovarian Cancer EnvironmentCancer Research, 2011
- Tumor-Infiltrating CD8+Lymphocytes Predict Clinical Outcome in Breast CancerJournal of Clinical Oncology, 2011
- Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T‐cell infiltration and positioning of malignant B cellsInternational Journal of Cancer, 2010
- Mycobacterium bovis Bacillus Calmette-Guérin (BCG)-induced activation of PI3K/Akt and NF-kB signaling pathways regulates expression of CXCL10 in epithelial cellsCellular Immunology, 2009
- Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation of CXCR3+ T cells in lymphocyte‐rich gastric carcinomaThe Journal of Pathology, 2008
- High Number of Intraepithelial CD8+ Tumor-Infiltrating Lymphocytes Is Associated with the Absence of Lymph Node Metastases in Patients with Large Early-Stage Cervical CancerCancer Research, 2007
- Effector Memory T Cells, Early Metastasis, and Survival in Colorectal CancerNew England Journal of Medicine, 2005
- Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survivalNature Medicine, 2004
- TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCGJournal of Leukocyte Biology, 2003